NCT00284518 - Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2010

Conditions

Benign Prostatic Hyperplasia

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.

DRUG

normal saline

Normal Saline (Placebo) transperineal or transrectal injection on Day 1.

Trial Locations (11)

Murdoch

Vienna

Victoria

Olomouc

Paris

Braunschweig

Perugia

Martin

Seoul

Taipei

London